ES2193337T3 - Utilizacion de sales de estroncio para el tratamiento de la artrosis. - Google Patents

Utilizacion de sales de estroncio para el tratamiento de la artrosis.

Info

Publication number
ES2193337T3
ES2193337T3 ES97401362T ES97401362T ES2193337T3 ES 2193337 T3 ES2193337 T3 ES 2193337T3 ES 97401362 T ES97401362 T ES 97401362T ES 97401362 T ES97401362 T ES 97401362T ES 2193337 T3 ES2193337 T3 ES 2193337T3
Authority
ES
Spain
Prior art keywords
treatment
artrosis
strontium salts
strontium
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97401362T
Other languages
English (en)
Inventor
Yannis Tsouderos
Pascale Deloffre
Michel Wierzbicki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Application granted granted Critical
Publication of ES2193337T3 publication Critical patent/ES2193337T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE SALES DE ESTRONCIO PARA LA OBTENCION DE COMPOSICIONES FARMACEUTICAS DESTINADAS A LA PREVENCION Y AL TRATAMIENTO DE LA ARTROSIS.
ES97401362T 1996-06-17 1997-06-16 Utilizacion de sales de estroncio para el tratamiento de la artrosis. Expired - Lifetime ES2193337T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9607475A FR2749759B1 (fr) 1996-06-17 1996-06-17 Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose

Publications (1)

Publication Number Publication Date
ES2193337T3 true ES2193337T3 (es) 2003-11-01

Family

ID=9493102

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97401362T Expired - Lifetime ES2193337T3 (es) 1996-06-17 1997-06-16 Utilizacion de sales de estroncio para el tratamiento de la artrosis.

Country Status (16)

Country Link
US (1) US5856356A (es)
EP (1) EP0813869B1 (es)
JP (1) JP3935557B2 (es)
CN (1) CN1136856C (es)
AT (1) ATE233558T1 (es)
AU (1) AU711950B2 (es)
BR (1) BR9703603A (es)
CA (1) CA2206837C (es)
DE (1) DE69719408T2 (es)
DK (1) DK0813869T3 (es)
ES (1) ES2193337T3 (es)
FR (1) FR2749759B1 (es)
HU (1) HU227935B1 (es)
NO (1) NO315840B1 (es)
NZ (1) NZ328106A (es)
ZA (1) ZA975323B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
FR2828206B1 (fr) * 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
FR2844797B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844795B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2846558B1 (fr) * 2002-11-05 2006-07-14 Servier Lab Utilisation du sel distrontique de l'acide 2-n,n-di(carboxymethyl)amino-3-cyano-4-carboxymethyl- thiophene-5-carboxylique pour l'obtention de medicaments destines au traitement des douleurs gastro-duodenales
CA2561082C (en) * 2003-03-27 2014-07-15 Santosolve As Anti-inflammatory treatment based on strontium compounds
EP1622629B1 (en) * 2003-05-07 2013-07-10 Osteologix A/S Controlled-release composition containing a strontium salt
ES2394782T3 (es) * 2003-05-07 2013-02-05 Osteologix A/S Composición con estroncio y vitamina D para la profilaxis y/o tratamiento de afecciones de cartílagos y/o huesos
EP1745791B1 (en) * 2003-05-07 2013-06-26 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
US7927626B2 (en) 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
CA2557324C (en) * 2004-02-26 2012-10-16 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
EP1744770A2 (en) * 2004-05-06 2007-01-24 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
US20090035315A1 (en) * 2004-06-17 2009-02-05 Stephan Christgau Method of Improving Treatments in Rheumatic and Arthritic Diseases
AU2005254154A1 (en) * 2004-06-17 2005-12-29 Osteologix A/S Improving pain treatment with strontium combinations
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
CN101018586B (zh) * 2004-06-25 2014-08-27 莫克瓦洛Spf有限公司 含锶和维生素d的组合物及其用途
ATE443541T1 (de) * 2004-06-25 2009-10-15 Strontin Aps Zusammensetzungen mit strontium und vitamin d und ihre verwendungen
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
LT2801354T (lt) 2004-10-08 2017-06-26 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
EP1855654A1 (en) * 2005-02-28 2007-11-21 Osteologix A/S Tablets comprising a high load of strontium
FR2899895B1 (fr) * 2006-04-12 2010-09-17 Servier Lab Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9421302B2 (en) 2006-05-26 2016-08-23 Baxter International Inc. Injectable fibrin composition for bone augmentation
GB0612028D0 (en) * 2006-06-16 2006-07-26 Imp Innovations Ltd Bioactive glass
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
CN101204375B (zh) * 2006-12-19 2010-09-29 北京德众万全药物技术开发有限公司 一种雷奈酸锶干混悬剂
ES2573327T3 (es) * 2007-04-23 2016-06-07 Baxter International Inc. Composiciones de fibrina que contienen compuestos de estroncio
GB0713094D0 (en) * 2007-07-05 2007-08-15 Imp Innovations Ltd Glass polycarboxylate cements
GB0724556D0 (en) * 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
CN102014973A (zh) 2008-02-29 2011-04-13 弗罗桑医疗设备公司 用于促进止血和/或伤口愈合的装置
WO2009144455A2 (en) * 2008-05-27 2009-12-03 Imperial Innovations Limited Process for producing porous scaffolds from sinterable glass
GB0809592D0 (en) * 2008-05-27 2008-07-02 Imp Innovations Ltd Biomaterials
WO2010079222A1 (en) 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
GB0911365D0 (en) 2009-06-30 2009-08-12 Bioceramic Therapeutics Ltd Multicomponent glasses for use as coatings and in personal care products
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
WO2011110597A1 (de) 2010-03-11 2011-09-15 Azad Pharmaceutical Ingredients Ag Verfahren zur herstellung von strontiumranelat
SA111320355B1 (ar) 2010-04-07 2015-01-08 Baxter Heathcare S A إسفنجة لايقاف النزف
KR101957625B1 (ko) 2010-06-01 2019-03-12 백스터 인터내셔널 인코포레이티드 건조 및 안정한 지혈 조성물의 제조 방법
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
JP6195569B2 (ja) 2011-10-11 2017-09-13 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 止血組成物
ES2938566T3 (es) 2011-10-11 2023-04-12 Baxter Int Composiciones hemostaticas
PT2771027E (pt) 2011-10-27 2015-11-26 Baxter Healthcare Sa Composições hemostáticas
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
EP2977066A3 (en) 2012-06-12 2016-07-27 Ferrosan Medical Devices A/S Dry haemostatic composition
AU2014283170B2 (en) 2013-06-21 2017-11-02 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
JP6489485B2 (ja) 2013-12-11 2019-03-27 フェロサン メディカル デバイシーズ エイ／エス 押し出し増強因子を含んでいる乾燥組成物
AU2015333206B2 (en) 2014-10-13 2019-07-11 Ferrosan Medical Devices A/S. Dry composition for use in haemostasis and wound healing
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
CN107771093B (zh) 2015-07-03 2021-06-15 弗罗桑医疗设备公司 用于混合两种组分和用于在存储条件下保持真空的注射器
WO2018084959A2 (en) 2016-09-30 2018-05-11 Nelson Deanna J Pharmaceutical quality strontium l-lactate
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152431A (en) * 1977-09-22 1979-05-01 William H. Rorer, Inc. Compositions and method of use
FR2633619B1 (fr) * 1988-06-29 1991-02-08 Adir Nouveau sel de strontium, son procede de preparation et les compositions pharmaceutiques le renfermant
FR2651497B1 (fr) * 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
HUP9701059A3 (en) 1998-05-28
DK0813869T3 (da) 2003-06-02
NO972764L (no) 1997-12-18
US5856356A (en) 1999-01-05
AU2490297A (en) 1998-01-08
FR2749759A1 (fr) 1997-12-19
CN1136856C (zh) 2004-02-04
JPH1059852A (ja) 1998-03-03
DE69719408D1 (de) 2003-04-10
JP3935557B2 (ja) 2007-06-27
FR2749759B1 (fr) 1999-11-26
EP0813869B1 (fr) 2003-03-05
BR9703603A (pt) 1998-09-01
HU9701059D0 (en) 1997-08-28
ATE233558T1 (de) 2003-03-15
NO315840B1 (no) 2003-11-03
AU711950B2 (en) 1999-10-28
ZA975323B (en) 1998-01-14
CN1179944A (zh) 1998-04-29
NZ328106A (en) 2001-04-27
HUP9701059A2 (hu) 1998-03-02
NO972764D0 (no) 1997-06-16
EP0813869A1 (fr) 1997-12-29
CA2206837C (fr) 2002-12-03
CA2206837A1 (fr) 1997-12-17
HU227935B1 (en) 2012-06-28
DE69719408T2 (de) 2003-12-24

Similar Documents

Publication Publication Date Title
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
PT1235799E (pt) Forma polimorfica de atorvastatina-calcio
BR9713363A (pt) Epotilonas c, d, e e f, preparação e composições
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
UY25157A1 (es) Composiciones farmacéuticas conteniendo atorvastatina y amlodipino
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
ES2194107T3 (es) Formulaciones farmaceuticas y dieteticas para la profilaxis y tratamiento de trastornos gastrointestinales.
CY1105125T1 (el) Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων
MX9701385A (es) Preparacion de producto combinado para usarse en enfermedades inmunologicas.
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
SE9802208D0 (sv) Novel compounds
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
ES2192704T3 (es) Innovadoras composiciones farmaceuticas.
SE9901077D0 (sv) Novel use
SE9801494D0 (sv) Novel use
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
DE69819539D1 (de) Antithrombotische mittel
SE9802209D0 (sv) Novel compounds
DK0977871T3 (da) Neurotrypsin
AR025379A1 (es) 9a-azalidas con actividad antibacteriana.